1. Hyperuricemia And Estimated Cardiovascular Risk Among Migrant and non-migrant Africans. (13th November 2019) Authors: Agyemang, C; Mannens, M A M; Henneman, P; Beune, E; Meeks, K; Requena-Mendez, A Journal: European journal of public health Issue: Volume 29(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP03 Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn's disease patients: The EPIC-CD study. (30th January 2023) Authors: Joustra, V; Li Yim, A; Hageman, I; Levin, E; Noble, A; Chapman, T; McGregor, C; Adams, A; Satsangi, J; de Jonge, W; Henneman, P; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP29 Peripheral blood DNA methylation biomarkers accurately predict clinical- and endoscopic response to vedolizumab in a real-life cohort of Crohn's Disease patients. (21st January 2022) Authors: Joustra, V; Hageman, I; Li Yim, A; Levin, E; Satsangi, J; Adams, A; De Jonge, W; Henneman, P; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i032 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P198 An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn's Disease. (21st January 2022) Authors: Radford-Smith, D; Yates, A; Hageman, I; Joustra, V; Li Yim, A; Davids, M; Henneman, P; Hakvoort, T; D'Haens, G; de Jong, W; Anthony, D; Satsangi, J; Probert, F Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P707 Microbial signature of the colon is not associated with response to vedolizumab in Crohn's disease. (21st January 2022) Authors: Hageman, I; Joustra, V; Li Yim, A; Davids, M; Henneman, P; Hakvoort, T; Probert, F; Satsangi, J; D'Haens, G; De Jonge, W Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen Family study. Issue 9 (11th June 2008) Authors: Henneman, P; Aulchenko, Y S; Frants, R R; van Dijk, K W; Oostra, B A; van Duijn, C M Journal: Journal of medical genetics Issue: Volume 45:Issue 9(2008) Page Start: 572 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗